Blood accessibility to fibrin in venous thrombosis is thrombus age-dependent and predicts fibrinolytic efficacy: An in vivo fibrin molecular imaging study

Ashley F. Stein-Merlob, Chase W. Kessinger, S. Sibel Erdem, Henry Zelada, Scott A. Hilderbrand, Charles P. Lin, Guillermo J. Tearney, Michael R. Jaff, Guy Reed, Peter K. Henke, Jason R. McCarthy, Farouc A. Jaffer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Fibrinolytic therapy of venous thromboembolism (VTE) is increasingly utilized, yet limited knowledge is available regarding in vivo mechanisms that govern fibrinolytic efficacy. In particular, it is unknown how age-dependent thrombus organization limits direct blood contact with fibrin, the target of blood-based fibrinolytic agents. Utilizing high-resolution in vivo optical molecular imaging with FTP11, a near-infrared fluorescence (NIRF) fibrin-specific reporter, here we investigated the in vivo interrelationships of blood accessibility to fibrin, thrombus age, thrombus neoendothelialization, and fibrinolysis in murine venous thrombosis (VT). In both stasis VT and non-stasis VT, NIRF microscopy showed that FTP11 fibrin binding was thrombus age-dependent. FTP11 localized to the luminal surface of early-stage VT, but only minimally to subacute VT (p<0.001). Transmission electron microscopy of early stage VT revealed direct blood cell contact with luminal fibrin-rich surfaces. In contrast, subacute VT exhibited an encasing CD31+ neoendothelial layer that limited blood cell contact with thrombus fibrin in both VT models. Next we developed a theranostic strategy to predict fibrinolytic efficacy based on the in vivo fibrin accessibility to blood NIRF signal. Mice with variably aged VT underwent FTP11 injection and intravital microscopy (IVM), followed by tissue plasminogen activator infusion to induce VT fibrinolysis. Fibrin molecular IVM revealed that early stage VT, but not subacute VT, bound FTP11 (p<0.05), and experienced higher rates of fibrinolysis and total fibrinolysis (p<0.05 vs. subacute VT). Before fibrinolysis, the baseline FTP11 NIRF signal predicted the net fibrinolysis at 60 minutes (p<0.001). Taken together, these data provide novel insights into the temporal evolution of VT and its susceptibility to therapeutic fibrinolysis. Fibrin molecular imaging may provide a theranostic strategy to identify venous thrombi amenable to fibrinolytic therapies.

Original languageEnglish (US)
Pages (from-to)1317-1327
Number of pages11
JournalTheranostics
Volume5
Issue number12
DOIs
StatePublished - Jan 1 2015

Fingerprint

Molecular Imaging
Fibrin
Venous Thrombosis
Thrombosis
Fibrinolysis
Fluorescence
Thrombolytic Therapy
Blood Cells
Fibrinolytic Agents
Optical Imaging
Venous Thromboembolism
Tissue Plasminogen Activator
Transmission Electron Microscopy
Fluorescence Microscopy

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Stein-Merlob, A. F., Kessinger, C. W., Sibel Erdem, S., Zelada, H., Hilderbrand, S. A., Lin, C. P., ... Jaffer, F. A. (2015). Blood accessibility to fibrin in venous thrombosis is thrombus age-dependent and predicts fibrinolytic efficacy: An in vivo fibrin molecular imaging study. Theranostics, 5(12), 1317-1327. https://doi.org/10.7150/thno.12494

Blood accessibility to fibrin in venous thrombosis is thrombus age-dependent and predicts fibrinolytic efficacy : An in vivo fibrin molecular imaging study. / Stein-Merlob, Ashley F.; Kessinger, Chase W.; Sibel Erdem, S.; Zelada, Henry; Hilderbrand, Scott A.; Lin, Charles P.; Tearney, Guillermo J.; Jaff, Michael R.; Reed, Guy; Henke, Peter K.; McCarthy, Jason R.; Jaffer, Farouc A.

In: Theranostics, Vol. 5, No. 12, 01.01.2015, p. 1317-1327.

Research output: Contribution to journalArticle

Stein-Merlob, AF, Kessinger, CW, Sibel Erdem, S, Zelada, H, Hilderbrand, SA, Lin, CP, Tearney, GJ, Jaff, MR, Reed, G, Henke, PK, McCarthy, JR & Jaffer, FA 2015, 'Blood accessibility to fibrin in venous thrombosis is thrombus age-dependent and predicts fibrinolytic efficacy: An in vivo fibrin molecular imaging study', Theranostics, vol. 5, no. 12, pp. 1317-1327. https://doi.org/10.7150/thno.12494
Stein-Merlob, Ashley F. ; Kessinger, Chase W. ; Sibel Erdem, S. ; Zelada, Henry ; Hilderbrand, Scott A. ; Lin, Charles P. ; Tearney, Guillermo J. ; Jaff, Michael R. ; Reed, Guy ; Henke, Peter K. ; McCarthy, Jason R. ; Jaffer, Farouc A. / Blood accessibility to fibrin in venous thrombosis is thrombus age-dependent and predicts fibrinolytic efficacy : An in vivo fibrin molecular imaging study. In: Theranostics. 2015 ; Vol. 5, No. 12. pp. 1317-1327.
@article{0eb3a67208d046b890b80c933fd703f4,
title = "Blood accessibility to fibrin in venous thrombosis is thrombus age-dependent and predicts fibrinolytic efficacy: An in vivo fibrin molecular imaging study",
abstract = "Fibrinolytic therapy of venous thromboembolism (VTE) is increasingly utilized, yet limited knowledge is available regarding in vivo mechanisms that govern fibrinolytic efficacy. In particular, it is unknown how age-dependent thrombus organization limits direct blood contact with fibrin, the target of blood-based fibrinolytic agents. Utilizing high-resolution in vivo optical molecular imaging with FTP11, a near-infrared fluorescence (NIRF) fibrin-specific reporter, here we investigated the in vivo interrelationships of blood accessibility to fibrin, thrombus age, thrombus neoendothelialization, and fibrinolysis in murine venous thrombosis (VT). In both stasis VT and non-stasis VT, NIRF microscopy showed that FTP11 fibrin binding was thrombus age-dependent. FTP11 localized to the luminal surface of early-stage VT, but only minimally to subacute VT (p<0.001). Transmission electron microscopy of early stage VT revealed direct blood cell contact with luminal fibrin-rich surfaces. In contrast, subacute VT exhibited an encasing CD31+ neoendothelial layer that limited blood cell contact with thrombus fibrin in both VT models. Next we developed a theranostic strategy to predict fibrinolytic efficacy based on the in vivo fibrin accessibility to blood NIRF signal. Mice with variably aged VT underwent FTP11 injection and intravital microscopy (IVM), followed by tissue plasminogen activator infusion to induce VT fibrinolysis. Fibrin molecular IVM revealed that early stage VT, but not subacute VT, bound FTP11 (p<0.05), and experienced higher rates of fibrinolysis and total fibrinolysis (p<0.05 vs. subacute VT). Before fibrinolysis, the baseline FTP11 NIRF signal predicted the net fibrinolysis at 60 minutes (p<0.001). Taken together, these data provide novel insights into the temporal evolution of VT and its susceptibility to therapeutic fibrinolysis. Fibrin molecular imaging may provide a theranostic strategy to identify venous thrombi amenable to fibrinolytic therapies.",
author = "Stein-Merlob, {Ashley F.} and Kessinger, {Chase W.} and {Sibel Erdem}, S. and Henry Zelada and Hilderbrand, {Scott A.} and Lin, {Charles P.} and Tearney, {Guillermo J.} and Jaff, {Michael R.} and Guy Reed and Henke, {Peter K.} and McCarthy, {Jason R.} and Jaffer, {Farouc A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.7150/thno.12494",
language = "English (US)",
volume = "5",
pages = "1317--1327",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "12",

}

TY - JOUR

T1 - Blood accessibility to fibrin in venous thrombosis is thrombus age-dependent and predicts fibrinolytic efficacy

T2 - An in vivo fibrin molecular imaging study

AU - Stein-Merlob, Ashley F.

AU - Kessinger, Chase W.

AU - Sibel Erdem, S.

AU - Zelada, Henry

AU - Hilderbrand, Scott A.

AU - Lin, Charles P.

AU - Tearney, Guillermo J.

AU - Jaff, Michael R.

AU - Reed, Guy

AU - Henke, Peter K.

AU - McCarthy, Jason R.

AU - Jaffer, Farouc A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Fibrinolytic therapy of venous thromboembolism (VTE) is increasingly utilized, yet limited knowledge is available regarding in vivo mechanisms that govern fibrinolytic efficacy. In particular, it is unknown how age-dependent thrombus organization limits direct blood contact with fibrin, the target of blood-based fibrinolytic agents. Utilizing high-resolution in vivo optical molecular imaging with FTP11, a near-infrared fluorescence (NIRF) fibrin-specific reporter, here we investigated the in vivo interrelationships of blood accessibility to fibrin, thrombus age, thrombus neoendothelialization, and fibrinolysis in murine venous thrombosis (VT). In both stasis VT and non-stasis VT, NIRF microscopy showed that FTP11 fibrin binding was thrombus age-dependent. FTP11 localized to the luminal surface of early-stage VT, but only minimally to subacute VT (p<0.001). Transmission electron microscopy of early stage VT revealed direct blood cell contact with luminal fibrin-rich surfaces. In contrast, subacute VT exhibited an encasing CD31+ neoendothelial layer that limited blood cell contact with thrombus fibrin in both VT models. Next we developed a theranostic strategy to predict fibrinolytic efficacy based on the in vivo fibrin accessibility to blood NIRF signal. Mice with variably aged VT underwent FTP11 injection and intravital microscopy (IVM), followed by tissue plasminogen activator infusion to induce VT fibrinolysis. Fibrin molecular IVM revealed that early stage VT, but not subacute VT, bound FTP11 (p<0.05), and experienced higher rates of fibrinolysis and total fibrinolysis (p<0.05 vs. subacute VT). Before fibrinolysis, the baseline FTP11 NIRF signal predicted the net fibrinolysis at 60 minutes (p<0.001). Taken together, these data provide novel insights into the temporal evolution of VT and its susceptibility to therapeutic fibrinolysis. Fibrin molecular imaging may provide a theranostic strategy to identify venous thrombi amenable to fibrinolytic therapies.

AB - Fibrinolytic therapy of venous thromboembolism (VTE) is increasingly utilized, yet limited knowledge is available regarding in vivo mechanisms that govern fibrinolytic efficacy. In particular, it is unknown how age-dependent thrombus organization limits direct blood contact with fibrin, the target of blood-based fibrinolytic agents. Utilizing high-resolution in vivo optical molecular imaging with FTP11, a near-infrared fluorescence (NIRF) fibrin-specific reporter, here we investigated the in vivo interrelationships of blood accessibility to fibrin, thrombus age, thrombus neoendothelialization, and fibrinolysis in murine venous thrombosis (VT). In both stasis VT and non-stasis VT, NIRF microscopy showed that FTP11 fibrin binding was thrombus age-dependent. FTP11 localized to the luminal surface of early-stage VT, but only minimally to subacute VT (p<0.001). Transmission electron microscopy of early stage VT revealed direct blood cell contact with luminal fibrin-rich surfaces. In contrast, subacute VT exhibited an encasing CD31+ neoendothelial layer that limited blood cell contact with thrombus fibrin in both VT models. Next we developed a theranostic strategy to predict fibrinolytic efficacy based on the in vivo fibrin accessibility to blood NIRF signal. Mice with variably aged VT underwent FTP11 injection and intravital microscopy (IVM), followed by tissue plasminogen activator infusion to induce VT fibrinolysis. Fibrin molecular IVM revealed that early stage VT, but not subacute VT, bound FTP11 (p<0.05), and experienced higher rates of fibrinolysis and total fibrinolysis (p<0.05 vs. subacute VT). Before fibrinolysis, the baseline FTP11 NIRF signal predicted the net fibrinolysis at 60 minutes (p<0.001). Taken together, these data provide novel insights into the temporal evolution of VT and its susceptibility to therapeutic fibrinolysis. Fibrin molecular imaging may provide a theranostic strategy to identify venous thrombi amenable to fibrinolytic therapies.

UR - http://www.scopus.com/inward/record.url?scp=84954481110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954481110&partnerID=8YFLogxK

U2 - 10.7150/thno.12494

DO - 10.7150/thno.12494

M3 - Article

C2 - 26516370

AN - SCOPUS:84954481110

VL - 5

SP - 1317

EP - 1327

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 12

ER -